Key takeaways for New Jersey
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • NJ FamilyCare coverage rules apply for Prediabetes patients in New Jersey — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
New Jersey-specific context
New Jersey has telehealth access concentrated in Newark, Jersey City, Paterson metros, with additional reach to Elizabeth and Edison. RWJBarnabas Health, Hackensack Meridian Health, Atlantic Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nj.gov/health.
New Jerseytelehealth & pricing rules
- • New Jersey requires a live video consultation before a GLP-1 prescription.
- • New Jersey allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Jersey: ~$328/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.